127 related articles for article (PubMed ID: 37993370)
1. Men's Acceptance of Screening for Prostate Cancer with Prostate-specific Antigen, Magnetic Resonance Imaging, and Prostate Biopsy.
Godtman RA; Pettersson C; Svensson L; Kohestani K; Stinesen Bratt K; Wallström J; Månsson M; Hellström M; Hugosson J
Eur Urol Oncol; 2024 Jun; 7(3):553-562. PubMed ID: 37993370
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
3. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
[TBL] [Abstract][Full Text] [Related]
4. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
5. An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study.
Eldred-Evans D; Tam H; Sokhi H; Padhani AR; Connor M; Price D; Gammon M; Klimowska-Nassar N; Burak P; Day E; Winkler M; Fiorentino F; Ahmed HU
Eur Urol Oncol; 2023 Jun; 6(3):295-302. PubMed ID: 37080821
[TBL] [Abstract][Full Text] [Related]
6. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
[TBL] [Abstract][Full Text] [Related]
7. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
[TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial.
Wallström J; Geterud K; Kohestani K; Maier SE; Pihl CG; Socratous A; Stranne J; Arnsrud-Godtman R; Månsson M; Hellström M; Hugosson J
Eur Urol Oncol; 2022 Feb; 5(1):54-60. PubMed ID: 34580053
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
Auvinen A; Tammela TLJ; Mirtti T; Lilja H; Tolonen T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Natunen K; Nevalainen J; Raitanen J; Ronkainen J; van der Kwast T; Riikonen J; Pétas A; Matikainen M; Taari K; Kilpeläinen T; Rannikko AS;
JAMA; 2024 May; 331(17):1452-1459. PubMed ID: 38581254
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
Boschheidgen M; Albers P; Schlemmer HP; Hellms S; Bonekamp D; Sauter A; Hadaschik B; Krilaviciute A; Radtke JP; Seibold P; Lakes J; Arsov C; Gschwend JE; Herkommer K; Makowski M; Kuczyk MA; Wacker F; Harke N; Debus J; Körber SA; Benner A; Kristiansen G; Giesel FL; Antoch G; Kaaks R; Becker N; Schimmöller L
Eur Urol; 2024 Feb; 85(2):105-111. PubMed ID: 37863727
[TBL] [Abstract][Full Text] [Related]
11. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
[TBL] [Abstract][Full Text] [Related]
12. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
13. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.
Sonn GA; Chang E; Natarajan S; Margolis DJ; Macairan M; Lieu P; Huang J; Dorey FJ; Reiter RE; Marks LS
Eur Urol; 2014 Apr; 65(4):809-15. PubMed ID: 23523537
[TBL] [Abstract][Full Text] [Related]
14. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
15. Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
Avery KN; Metcalfe C; Vedhara K; Lane JA; Davis M; Neal DE; Hamdy FC; Donovan JL; Blazeby JM
Eur Urol; 2012 Oct; 62(4):649-55. PubMed ID: 22244151
[TBL] [Abstract][Full Text] [Related]
16. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.
Eldred-Evans D; Burak P; Connor MJ; Day E; Evans M; Fiorentino F; Gammon M; Hosking-Jervis F; Klimowska-Nassar N; McGuire W; Padhani AR; Prevost AT; Price D; Sokhi H; Tam H; Winkler M; Ahmed HU
JAMA Oncol; 2021 Mar; 7(3):395-402. PubMed ID: 33570542
[TBL] [Abstract][Full Text] [Related]
17. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
18. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies.
Rais-Bahrami S; Siddiqui MM; Vourganti S; Turkbey B; Rastinehad AR; Stamatakis L; Truong H; Walton-Diaz A; Hoang AN; Nix JW; Merino MJ; Wood BJ; Simon RM; Choyke PL; Pinto PA
BJU Int; 2015 Mar; 115(3):381-8. PubMed ID: 24447678
[TBL] [Abstract][Full Text] [Related]
20. Magnetic Resonance Imaging Follow-up of Targeted Biopsy-negative Prostate Lesions.
Stavrinides V; Eksi E; Finn R; Texeira-Mendes L; Rana S; Trahearn N; Grey A; Giganti F; Huet E; Fiard G; Freeman A; Haider A; Allen C; Kirkham A; Cole AP; Collins T; Pendse D; Dickinson L; Punwani S; Pashayan N; Emberton M; Moore CM; Orczyk C
Eur Urol Focus; 2023 Sep; 9(5):781-787. PubMed ID: 37031096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
